# I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).

> **NCT03939689** · PHASE2 · COMPLETED · sponsor: **Progenics Pharmaceuticals, Inc.** · enrollment: 120 (actual)

## Conditions studied

- Metastatic Prostate Cancer
- Castration-resistant Prostate Cancer
- Prostatic Neoplasm
- Cancer of the Prostate
- Progressive mCRPC

## Interventions

- **DRUG:** I-131-1095
- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT03939689
- **Lead sponsor:** Progenics Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-30
- **Primary completion:** 2023-09-21
- **Final completion:** 2024-09-24
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2025-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03939689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03939689, "I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT03939689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*